Food Effect Study of D-0502 Tablet in Healthy Volunteers
This is an open label, randomized, balanced, single dose, two-treatment (fed vs. fasting), two-period, two-sequence crossover study of postmenopausal female healthy subjects.
Breast Cancer
DRUG: D-0502
Pharmacokinetic: area under the plasma concentration versus time curve (AUC), AUC: area under the plasma concentration versus time curve for D-0502; Unit: nM\*hr, Day 1 through 4, Day 7 through 11|Pharmacokinetic: maximum plasma drug concentration (Cmax), Cmax: maximum plasma drug concentration of D-0502; Unit: nM, Day 1 through 4, Day 7 through 11|Pharmacokinetic: Time to reach the Cmax (Tmax), Tmax: Time to reach the Cmax of D-0502; Unit: hr, Day 1 through 4, Day 7 through 11|Pharmacokinetic: Apparent terminal half-life (t1/2), t1/2: apparent terminal half-life of D-0502; Unit: hr, Day 1 through 4, Day 7 through 11
Incidence of Treatment-Emergent Adverse Events, Number of treatment-related adverse events as assessed by CTCAE v4.0, 2 weeks
This is an open label, randomized, balanced, single dose, two-treatment (fed vs. fasting), two-period, two-sequence crossover study of postmenopausal female healthy subjects.